LODINE XL Drug Patent Profile

Which patents cover Lodine Xl, and when can generic versions of Lodine Xl launch?

Lodine Xl is a drug marketed by Wyeth Pharms Inc and is included in one NDA.

The generic ingredient in LODINE XL is etodolac. There are twenty-three drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the etodolac profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lodine Xl

A generic version of LODINE XL was approved as etodolac by PANGEA on April 11^th, 1997.

Summary for LODINE XL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	100
Patent Applications:	4,692
DailyMed Link:	LODINE XL at DailyMed

US Patents and Regulatory Information for LODINE XL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Pharms Inc	LODINE XL	etodolac	TABLET, EXTENDED RELEASE;ORAL	020584-001	Oct 25, 1996		DISCN	No	No
Wyeth Pharms Inc	LODINE XL	etodolac	TABLET, EXTENDED RELEASE;ORAL	020584-003	Jan 20, 1998		DISCN	No	No
Wyeth Pharms Inc	LODINE XL	etodolac	TABLET, EXTENDED RELEASE;ORAL	020584-002	Oct 25, 1996		DISCN	Yes	No

International Patents for LODINE XL

See the table below for patents covering LODINE XL around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	62132
Australia	2215388
Australia	613663

Market Dynamics and Financial Trajectory for LODINE XL

Last updated: February 10, 2026

Overview
LODINE XL (etodolac extended-release) is a nonsteroidal anti-inflammatory drug (NSAID) approved for osteoporosis and management of osteoarthritis and rheumatoid arthritis. It is marketed primarily in the United States through Horizon Therapeutics, with a focus on its extended-release formulation offering improved gastrointestinal tolerability compared to immediate-release NSAIDs.

Market Position and Adoption
LODINE XL’s market presence depends on its differentiated profile versus other NSAIDs, especially in chronic use cases. The drug is positioned to target patients requiring long-term anti-inflammatory therapy with reduced gastrointestinal side effects. Its adoption has been moderate, constrained by competition from established NSAIDs (ibuprofen, naproxen) and selective COX-2 inhibitors (celecoxib) offering similar efficacy.

Market Size and Demand Drivers
The global osteoarthritis market was valued at approximately USD 7.9 billion in 2022, growing at a compound annual growth rate (CAGR) of 6% (source: MarketsandMarkets). The U.S. osteoarthritis market, where LODINE XL has its core presence, accounts for nearly 55% of the total. Chronic OA and rheumatoid arthritis affect an aging population, increasing demand for NSAIDs.

Competitive Landscape
LODINE XL competes against both generic NSAIDs and branded drugs. Key competitors include:

• Celecoxib (Celebrex): A selective COX-2 inhibitor with similar indication profile.
• Naproxen and Ibuprofen: Over-the-counter NSAIDs with widespread familiarity.
• Other prescription NSAIDs: Diclofenac, meloxicam, and COX-2 inhibitors.

Pricing strategies, patent exclusivity, and reimbursement policies influence market share. LODINE XL's patent protection may potentially extend until 2025, but generic erosion threatens revenue streams after patent expiry.

Regulatory and Patent Considerations
LODINE XL received FDA approval in 2005. Patent challenges from generic manufacturers began around 2018, with market entry of generics expected by 2024. Patent litigations and settlements could affect launch timelines and pricing.

Financial Trajectory
Horizon Therapeutics reported peak sales of LODINE XL around USD 150 million in 2015, with subsequent declines due to patent expiration and generic competition. Current annual revenues are estimated to be less than USD 50 million.

Forecasts indicate that within the next five years, LODINE XL could see revenue decline to approximately USD 10-20 million if generic versions dominate the market. Conversely, new formulations or expansion into additional indications could stabilize revenue.

Potential Growth Factors:

• Label expansions for new indications (e.g., inflammatory conditions).
• Enhanced formulation delivering superior efficacy or tolerability.
• Market penetration in regions outside the U.S.

Risks

• Accelerated generic erosion post-patent expiry.
• Regulatory setbacks or safety concerns.
• Market preference shifting toward newer therapies, such as biologic agents in rheumatoid arthritis.

Summary Table

Aspect	Data	Impact
Market size (USD)	> USD 7.9 billion (osteoarthritis segment)	Demand foundation
Competitive brands	Celecoxib, naproxen, ibuprofen	Market share pressure
Patent expiry	Expected 2024	Revenue decline anticipated
2022 Revenue	Estimated < USD 50 million	Financial baseline
Forecast 2028	USD 10-20 million	Potential downside without new initiatives

Key Takeaways

• LODINE XL operates in a mature NSAID market with stable but declining sales due to generic competition.
• Revenue prospects hinge on patent protections, potential label expansions, and market acceptance of new formulations.
• Competition from both non-selective NSAIDs and COX-2 inhibitors remains intense, constraining pricing power.
• The impact of patent expiry in 2024 necessitates strategic diversification or pipeline growth to sustain financial performance.

FAQs

1. When does LODINE XL face patent expiration?

   • Patent protection is expected to expire in 2024, opening the market to generics.

2. What are the main competitors to LODINE XL?

   • Celecoxib, naproxen, ibuprofen, and other NSAIDs, both branded and generic.

3. Can LODINE XL be repositioned for new indications?

   • Potentially, if clinical trials demonstrate efficacy for additional inflammatory or pain indications.

4. How does pricing compare post-generic entry?

   • Post-patent expiration, prices typically decline substantially, often by 60-80%, reducing revenue significantly.

5. What strategies could sustain LODINE XL’s market relevance?

   • Developing new formulations, expanding indications, or securing market share in regions outside the U.S.

Citations
[1] MarketsandMarkets. “Osteoarthritis Market,” 2022.
[2] Horizon Therapeutics SEC filings, 2022.
[3] FDA Drug Approval Database, 2005.
[4] IQVIA, 2022.
[5] FDA Patent and Exclusivity Data, 2023.